Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Biguanides are useful in reducing macroangiopathy in patients with type 2 diabetes.
“Current evidence demonstrates their usefulness in reducing macroangiopathy in patients with type 2 diabetes 5 , 6 , 7 , 8 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Intensive insulin therapy is effective in suppressing the progression of macroangiopathy in type 1 diabetes.
“Intensive insulin therapy that combines multiple insulin injection therapy and SMBG has been shown to also be effective in suppressing the progression of macroangiopathy (coronary artery disease, cerebrovascular disease, and peripheral artery disease) 6 , 7 (grade A: 100% agreement).”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Fenofibrates have the potential to suppress the progression of diabetic retinopathy in patients with type 2 diabetes complicated by dyslipidemia.
“Fenofibrates have been shown to have the potential to suppress the progression of diabetic retinopathy in patients with type 2 diabetes complicated by dyslipidemia 7 , 12 (grade B: 85% agreement).”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Glycemic control is useful for suppressing the onset/progression of diabetic retinopathy in patients with type 1 and type 2 diabetes.
“Glycemic control has been shown to be useful for suppressing the onset/progression of diabetic retinopathy in patients with type 1 and type 2 diabetes 5 , 6 , 7 , 8 (grade A: 100% agreement).”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Strict glycemic control suppresses the onset/progression of diabetic neuropathy.
“Strict glycemic control has been shown to suppress the onset/progression of diabetic neuropathy 6 , 7 , 8 (grade A: 90% agreement).”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
The treatment of periodontal disease leads to improvement in the glycemic status of some patients with type 2 diabetes.
“The treatment of periodontal disease has been shown to lead to improvement in the glycemic status of some patients with type 2 diabetes 6 , 7 (grade B: 86% agreement).”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Modification of lifestyle habits and correction of obesity are associated with amelioration of risk factors for cardiovascular events in patients with diabetes.
“The modification of lifestyle habits and the correction of obesity are recommended in patients with diabetes, given that these measures are shown to be associated with the amelioration of these risk factors 7 , 8 , 9 (grade A: 90% agreement).”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Uncritical use of insulin or sulfonylureas may promote obesity in patients with type 2 diabetes and obesity.
“The use of insulin or SUs should be minimized in patients with type 2 diabetes and obesity, given that their uncritical use may promote obesity 7 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Left untreated, obesity often becomes more severe in patients with diabetes and obesity receiving exclusive therapy for hyperglycemia.
“Left untreated, obesity often becomes more severe in patients with diabetes and obesity receiving exclusive therapy for hyperglycemia 7 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Medical nutrition therapy is effective against dyslipidemia in patients with diabetes.
“MNT has been shown to be effective against dyslipidemia in patients with diabetes 5 , 6 , 7 (grade A: 100% agreement).”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
The appetite-inhibitory and weight-reducing properties of GLP-1 receptor agonists may improve glycemic control in patients with type 2 diabetes and obesity.
“The appetite‐inhibitory and weight‐reducing properties of glucagon‐like peptide 1 (GLP‐1) receptor agonists may improve glycemic control in patients with type 2 diabetes and obesity 7 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
The presence of concomitant disease, such as diabetic complications, obesity, and hypertension, adversely affects the health status of mothers and their pregnancy outcomes.
“The presence of concomitant disease, such as diabetic complications, obesity and hypertension, is shown to adversely affect the health status of mothers and their pregnancy outcomes. Patients are to be assessed for presence of these concomitant diseases and treated before they become pregnant 6 , 7 , 8 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Infections such as emphysematous cholecystitis, organ or soft tissue abscesses, rhinocerebral mucormycosis, malignant external otitis, emphysematous cystitis, emphysematous pyelitis, necrotizing fasciitis, and Fournier's gangrene tend to have diabetes as an underlying disease.
“Infections, such as emphysematous cholecystitis, organ or soft tissue abscesses, rhinocerebral mucormycosis, malignant external otitis, emphysematous cystitis, emphysematous pyelitis, necrotizing fasciitis and Fournier’s gangrene, tend to have diabetes as an underlying disease 7 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
Overweight in childhood does not increase the risk of type 2 diabetes if it is resolved before adolescence.
“Overweight in childhood does not increase the risk, if it is resolved before adolescence 7 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [7]
The citation lists haven’t been fetched yet
References 14 · Cited by 19
- Authors
- Kawasaki, E., Maruyama, T., Imagawa, A., Awata, T., Ikegami, H., Uchigata, Y., Osawa, H., Kawabata, Y., Kobayashi, T., Shimada, A., Shimizu, I., Takahashi, K., Nagata, M., Makino, H., & Hanafusa, T.
- Affiliations
- Nagasaki University Hospital (JP)
- Social Insurance Saitama Chuo Hospital (JP)
- The University of Osaka (JP)
- Saitama Medical University (JP)
- Kindai University (JP)
- Tokyo Women's Medical University (JP)
- Ehime University Hospital (JP)
- University of Yamanashi (JP)
- Saiseikai Central Hospital (JP)
- Sakakibara Hospital (JP)
- Iwate Medical University (JP)
- Kakogawa City Hospital Organization (JP)
- Corresponding author
- Hanafusa, Toshiaki
- ORCID
- Venue
- Diabetology International
- Published
- 2013-09-08
- Volume
- 4
- Issue
- 4
- Pages
- 221-225
- ISSN
- 2190-1678 (ISSN-L)
- 2190-1686
- OpenAlex
- W263868151
- Cited by
- 19
- References
- 14
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 1 · 2020: 3 · 2019: 1 · 2018: 3 · 2014: 2
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetology International (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23591321)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- diagnostic criteria, diabetic ketoacidosis, diabetic ketosis, endogenous insulin secretion, fulminant type 1 diabetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
